国盛证券：维持科济药业-B(02171)“买入”评级长期看好公司发展

智通财经2023-09-28

智通财经APP获悉，国盛证券发布研究报告称，基于科济药业-B(02171)经营现状，下调盈利预测;预计2023-25年归母净利润为-7.9/-8.3/-6.5亿元。但长期看好科济药业发展，维持“买入”评级。公司宣布自研靶向Claudin18.2的CAR-T细胞CT041治疗转移性胰腺癌的两个病例报告在《JournalofHematology&Oncology》(IF23.186)发表。另宣布与美德...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2370225728?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-09-28 14:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2370225728","market":"us","top_or_hot":-1,"title":"国盛证券：维持科济药业-B(02171)“买入”评级 长期看好公司发展","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，国盛证券发布研究报告称，基于科济药业-B(02171)经营现状，下调盈利预测;预计2023-25年归母净利润为-7.9/-8.3/-6.5亿元。但长期看好科济药业发展，维持“买入”评级。公司宣布自研靶向Claudin18.2的CAR-T细胞CT041治疗转移性胰腺癌的两个病例报告在《JournalofHematology&Oncology》(IF23.186)发表。另宣布与美德...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1001094.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国盛证券：维持科济药业-B(02171)“买入”评级 长期看好公司发展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国盛证券：维持科济药业-B(02171)“买入”评级 长期看好公司发展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-28 14:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1001094.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，国盛证券发布研究报告称，基于科济药业-B(02171)经营现状，下调盈利预测;预计2023-25年归母净利润为-7.9/-8.3/-6.5亿元。但长期看好科济药业发展，维持“买入”评级。公司宣布自研靶向Claudin18.2的CAR-T细胞CT041治疗转移性胰腺癌的两个病例报告在《JournalofHematology&Oncology》(IF23.186)发表。另宣布与美德...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1001094.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1001094.html","article_id":"2370225728","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2370225728","pubTimestamp":1695883613,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，国盛证券发布研究报告称，基于科济药业-B经营现状，下调盈利预测;预计2023-25年归母净利润为-7.9/-8.3/-6.5亿元。但长期看好科济药业发展，维持“买入”评级。潜在首款实体瘤CAR-T疗法CT041已进入确证性临床，合作Moderna拓宽应用边界。本次与Moderna达成合作，CT041联用CLDN18.2mRNA癌症疫苗开展临床前研究和I期临床，公司研发能力获得海外药企认可。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"02171":"科济药业-B"},"translate_title":"Guosheng Securities: Maintain Keji Pharmaceutical-B (02171) \"Buy\" rating and be optimistic about the company's development for a long time","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"智通财经APP获悉，国盛证券发布研究报告称，基于科济药业-B(02171)经营现状，下调盈利预测;预计2023-25年归母净利润为-7.9/-8.3/-6.5亿元。但长期看好科济药业发展，维持“买入”评级。公司宣布自研靶向Claudin18.2的CAR-T细胞CT041治疗转移性胰腺癌的两个病例报告在《JournalofHematology&Oncology》(IF23.186)发表。另宣布与美德纳公司(Nasdaq:MRNA)已启动一项合作协议，以研究科济药业的Claudin18.2CAR-T候选产品(CT041)与美德纳的试验性Claudin18.2mRNA癌症疫苗的组合效果。报告中称，两例患者的外周血CAR拷贝数均在输注后迅速升高并于2周内达到峰值;同时，流式细胞学检测结果均显示其外周血CD8+T细胞和Treg细胞比例增加，CD4+T细胞和B细胞比例减少，此类免疫细胞表型变化比细胞因子水平变化更加持久。潜在首款实体瘤CAR-T疗法CT041已进入确证性临床，合作Moderna拓宽应用边界。靶向CLDN18.2的CAR-T疗法CT041为全球首款进入确证性临床的实体瘤治疗CAR-T细胞候选药物，2022年3月完成中国确证性2期临床首例GC/GEJ患者入组、2023年4月获CDE批准开展用于Claudin18.2表达阳性的胰腺癌术后辅助治疗临床试验、2023年5月启动治疗至少二线治疗失败的Claudin18.2表达阳性GC/GEJ的美国2期临床。本次与Moderna达成合作，CT041联用CLDN18.2mRNA癌症疫苗开展临床前研究和I期临床，公司研发能力获得海外药企认可。报告中称，公司专注实体瘤、血液瘤细胞疗法研发，形成囊括多款CAR-T产品的创新管线，目前1个产品已提交上市申请，8个产品处于临床研发阶段，3个处于临床前阶段。针对CLDN18.2阳性消化道肿瘤的CT041和针对肝癌的CT011研发全球领先，产品设计差异化、布局全球化。同时为顺应细胞治疗行业发展趋势，前瞻建立了整合的细胞治疗平台，布局下一代实体瘤CAR-T和通用CAR-T技术，保持行业竞争优势。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2370225728","isCrawlerRequest":true}

国盛证券：维持科济药业-B(02171)“买入”评级 长期看好公司发展

精彩评论

国盛证券：维持科济药业-B(02171)“买入”评级长期看好公司发展